Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma-Reference-Cited by-同舟云学术

Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma

Published:2024-07-25 Issue:4 Volume:144 Page:457-461
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Godfrey James K.¹^ORCID,Gao Lei¹,Shouse Geoffrey¹^ORCID,Song Joo Y.²,Pak Stacy³,Lee Brian³^ORCID,Chen Bihong T.⁴,Kallam Avyakta¹,Baird John H.¹^ORCID,Marcucci Guido¹,Ghoda Lucy⁵,Vauleon Stephanie⁶,Danilov Alexey V.¹,Herrera Alex F.¹^ORCID,Kwak Larry W.¹,Budde Lihua E.¹^ORCID

Affiliation:

1. 1Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA

2. 2Department of Pathology, City of Hope, Duarte, CA

3. 3Department of Pharmacy, City of Hope, Duarte, CA

4. 4Department of Diagnostic Radiology, City of Hope, Duarte, CA

5. 5Department of Hematological Malignancies and Translational Science, Beckman Research Institute of City of Hope, Duarte, CA

6. 6Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland

Abstract

Abstract Although CD20×CD3 bispecific antibodies are effective against systemic B-cell lymphomas, their efficacy in central nervous system (CNS) lymphoma is unknown. Here, we report the CD20×CD3 bispecific glofitamab penetrates the blood-brain barrier, stimulates immune-cell infiltration of CNS tumors, and induces clinical responses in patients with secondary CNS.

Publisher

American Society of Hematology

Link

https://ashpublications.org/blood/article-pdf/144/4/457/2235419/blood_bld-2024-024168-main.pdf

Reference17 articles.

1. Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies;Sun;Sci Transl Med,2015

2. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing;Engelberts;EBioMedicine,2020

3. CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies;Bacac;Clin Cancer Res,2018

4. Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities;Falchi;Blood,2023

5. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study;Budde;Lancet Oncol,2022

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SOHO State of the Art Updates and Next Questions | Current Evidence and Future Directions for Bispecific Antibodies in Large B-Cell Lymphoma;Clinical Lymphoma Myeloma and Leukemia;2024-05